Your browser doesn't support javascript.
loading
Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial.
Rabkin, Judith G; Wagner, Glenn J; McElhiney, Martin C; Rabkin, Richard; Lin, Shu Hsing.
Afiliação
  • Rabkin JG; New York State Psychiatric Institute, New York, NY 10032, USA. jgrl@Columbia.edu
J Clin Psychopharmacol ; 24(4): 379-85, 2004 Aug.
Article em En | MEDLINE | ID: mdl-15232328
ABSTRACT

BACKGROUND:

While testosterone's ameliorative effects on depressive disorders and fatigue in HIV-positive patients have been suggested in the literature, no placebo-controlled trial selecting for depressive disorders and including a standard antidepressant has been conducted. Accordingly, this double-blind trial was designed to determine whether testosterone, as well as fluoxetine, is superior to placebo for depression, fatigue, or both.

METHOD:

One hundred twenty-three men with HIV/AIDS with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition depressive disorder entered the 8-week trial and were randomized to testosterone (up to 400 mg IM testosterone cypionate biweekly), fluoxetine (up to 60 mg/d), or double placebo. Outcome variables were the Clinical Global Impressions Scale for mood and for fatigue, the Hamilton Rating Scale for Depression, and the Chalder Fatigue Scale.

RESULTS:

Ninety men completed the trial. In intention-to-treat analyses, mood response rates were 54%, 47%, and 44% for fluoxetine, testosterone, and placebo, respectively. Among completers, mood response rates were 70%, 57%, and 53%, respectively; in neither analysis were differences between treatments statistically significant. In contrast, testosterone was superior to fluoxetine and placebo for completers regarding fatigue. In intention-to-treat analysis, response rates were 39%, 56%, and 42% for fluoxetine, testosterone, and placebo, respectively, and for study completers, 41%, 63%, and 52%, respectively, (P < 0.05),

CONCLUSION:

While over 50% of patients treated with testosterone reported improved mood, this rate was not statistically superior to placebo. Thus, our findings do not support prescription of testosterone as a first-line treatment for depressive disorders in HIV-positive men. However, if validated in additional studies, testosterone may be a useful option for medically ill men experiencing significant fatigue as well as depression.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Testosterona / Fluoxetina / Síndrome da Imunodeficiência Adquirida / Transtorno Depressivo / Fadiga Tipo de estudo: Clinical_trials / Guideline Limite: Adult / Humans / Male / Middle aged Idioma: En Ano de publicação: 2004 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Testosterona / Fluoxetina / Síndrome da Imunodeficiência Adquirida / Transtorno Depressivo / Fadiga Tipo de estudo: Clinical_trials / Guideline Limite: Adult / Humans / Male / Middle aged Idioma: En Ano de publicação: 2004 Tipo de documento: Article